Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
May 21, 2026
CoreWeave (CRWV) Holds Steady on 2026 Revenue Targets in a Shifting AI Landscape

CoreWeave (CRWV) Holds Steady on 2026 Revenue Targets in a Shifting AI Landscape

Key Takeaways

  • CoreWeave maintained its full-year 2026 revenue guidance of $12 billion to $13 billion following Q1 results.
  • The company closed a $3.1 billion HPC infrastructure-backed loan facility in May 2026, marking a milestone in GPU financing access.
  • Analyst sentiment remains mixed, with recent downgrades to Neutral offset by raised price targets from firms such as Citi and Barclays.
  • CoreWeave launched Sandboxes in mid-May to support AI agent training and model evaluation, contributing to short-term positive price momentum.
  • Enterprise expansion, particularly in financial services, and benchmark leadership in inference speed continue to support long-term positioning in the AI infrastructure sector.

Where CRWV Fits in Today’s Market

In recent weeks, CoreWeave shares have moved in line with the broader volatility seen across AI infrastructure names. Shifting analyst views, fresh company milestones, and macroeconomic questions around technology spending have all played a role. Attention remains focused on how well the company can deliver against its growth targets while securing the capital needed for continued expansion. Overall sentiment toward specialized AI cloud providers stays constructive, though investors are clearly weighing competitive pressures and margin dynamics.

Recent Moves Influencing CRWV Price Action

CoreWeave released its first-quarter 2026 results in early May. Revenue came in as expected, and the company provided second-quarter guidance of $2.45 billion to $2.6 billion, which sat a bit below consensus. It reaffirmed the full-year 2026 revenue range of $12 billion to $13 billion and lifted the floor on its 2026 exit run rate to $18 billion. Shares initially moved lower after the update, partly because capital-expenditure guidance rose to a range of $31 billion to $35 billion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Mid-month news offered some offset. On May 14, CoreWeave introduced its Sandboxes platform, aimed at speeding up reinforcement learning, agent tool use, and model evaluation. The launch helped lift the stock as it highlighted the company’s effort to close the execution gap for AI agents. A few days later, on May 18, CoreWeave closed a $3.1 billion HPC infrastructure-backed delayed-draw term loan facility—the first publicly syndicated GPU-backed financing of its kind. Investors viewed the deal as a positive sign of improved access to large-scale funding.

Analyst notes added layers to the picture. D.A. Davidson moved coverage to Neutral from Buy, pointing to execution risks and thinner margins relative to the 2026 outlook. At the same time, Citi and Barclays both raised their price targets. Mixed options activity and insider selling, including a notable disposal by Chief Strategy Officer Brian Venturo, also colored short-term sentiment. Competitive signals, such as Nvidia’s disclosed positions in AI equities and talk of possible new entrants including a Google-Blackstone cloud venture, kept the focus on CoreWeave’s specialized GPU optimization and its traction in financial services.

Factors to Watch Through the Rest of 2026

As the year unfolds, the reaffirmed $12 billion to $13 billion revenue band and the higher exit-run-rate target will stay front of mind. Elevated capital-expenditure levels will also draw scrutiny as the company builds out GPU capacity for both training and inference workloads. Competition in the specialized cloud segment, including any new hardware alternatives such as TPUs, could affect pricing power and market share. Enterprise adoption trends, especially deeper penetration in financial services and other high-value areas, remain a core growth driver. Performance benchmarks in inference speed and price-performance, together with the rollout of offerings like Sandboxes, should help differentiate the platform. Regulatory issues around data-center development and financing, along with broader economic influences on tech budgets, will shape the backdrop. I often review management commentary on backlog conversion and margin trends to gauge sustainable progress.

How I Use Tickeron AI Tools in My Research

In my own work I find it helpful to combine traditional analysis with automated tools. One resource I turn to regularly is Tickeron’s AI Trading Bots. The platform offers a wide selection of bots covering different strategies, timeframes, and risk profiles, many of which have shown solid historical performance in volatile technology names. I review the latest performance data and risk metrics to see whether any automated approaches might complement my manual review of names like CoreWeave. You can explore the full list and current selections directly on the AI Trading Bots page.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CRWV

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


Momentum Indicator for CRWV turns positive, indicating new upward trend

CRWV saw its Momentum Indicator move above the 0 level on September 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator turned positive. In 18 of the 20 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for CRWV just turned positive on September 24, 2026. Looking at past instances where CRWV's MACD turned positive, the stock continued to rise in 12 of 14 cases over the following month. The odds of a continued upward trend are 86%.

CRWV moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CRWV crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 3 of 4 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

Following a +2.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRWV advanced for three days, in 76 of 82 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRWV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

CRWV broke above its upper Bollinger Band on September 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CRWV entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.337) is normal, around the industry mean (18.522). P/E Ratio (0.000) is within average values for comparable stocks, (158.311). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (5.721) is also within normal values, averaging (104.490).

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. CRWV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRWV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NASDAQ:PANW), Crowdstrike Holdings Inc (NASDAQ:CRWD), Twilio (NYSE:TWLO), Block Inc (NYSE:XYZ), NetApp (NASDAQ:NTAP), Okta (NASDAQ:OKTA), Zscaler (NASDAQ:ZS), MongoDB (NASDAQ:MDB).

Industry description

Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.

Market Cap

The average market capitalization across the Computer Communications Industry is 35.56B. The market cap for tickers in the group ranges from 48.8K to 3.78T. MSFT holds the highest valuation in this group at 3.78T. The lowest valued company is WMHI at 48.8K.

High and low price notable news

The average weekly price growth across all stocks in the Computer Communications Industry was 1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 22%. BIRD experienced the highest price growth at 45%, while HUBC experienced the biggest fall at -47%.

Volume

The average weekly volume growth across all stocks in the Computer Communications Industry was -13%. For the same stocks of the Industry, the average monthly volume growth was -13% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 70
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 91
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
CRWV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ComputerCommunications

Industry
N/A
Address
290 West Mount Pleasant Avenue
Phone
+1 973 270-9737
Employees
2189
Web
https://www.coreweave.com
Interact to see
Advertisement
I've been following Planet Labs PBC (PL) closely, and one aspect that stands out is its operation of the world's largest constellation of earth-imaging satellites. This setup delivers daily global coverage, giving it a clear edge in geospatial intelligence. The "one-to-many" model allows for scalable economics, setting it apart from legacy providers that depend on exclusive image sales. The platform combines satellite data with AI-driven analytics, targeting sectors such as agriculture, defense, forestry, and insurance.
United Therapeutics Corporation focuses on biotechnology innovations for chronic and life-threatening conditions, particularly in pulmonary diseases. The company's portfolio centers on treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), featuring products like Tyvaso (treprostinil inhalation solution), Orenitram (oral treprostinil), Remodulin, and Adcirca.
I've been following Rocket Pharmaceuticals (RCKT) closely as a late-stage biotech focused on gene therapies for rare pediatric diseases, using both lentiviral vector (LVV) and adeno-associated virus (AAV) platforms. What stands out to me is the company's strategic shift toward AAV-based cardiovascular programs—Danon disease, PKP2-ACM, and BAG3-DCM—which target areas with significant unmet needs and larger markets compared to traditional hematology indications. The recent FDA approval of KRESLADI marks Rocket's entry into commercialization, giving the team valuable launch experience and confirming the strength of its manufacturing setup.
I've been keeping an eye on KDK, and it's clear the company is well-positioned in the autonomous vehicle space, with a focus on AI-powered solutions for long-haul trucking, industrial applications, and defense. Founded in 2018 and based in Mountain View, California, Kodiak AI develops the Kodiak Driver—a modular, vehicle-agnostic virtual driver that integrates advanced AI software with hardware to enable driverless operations. This platform tackles key challenges like U.S. truck driver shortages and safety concerns, where human error accounts for over 85% of crashes.
SE stock declined -21% over the past 30 days, primarily triggered by a Q4 2025 earnings EPS miss despite revenue beat, leading to a sharp 16% single-day drop. Over the past quarter, the stock fell -37%, reflecting sustained pressure from analyst price target cuts and concerns over rising growth investments.
As I review the cybersecurity space, PANW stands out with its commanding position, holding a 28.4% share in network security as of 2024. This leadership stems from its evolution from point solutions to a unified platform that includes Strata for network security, Prisma for cloud and SASE, and Cortex for AI-powered security operations. The platformization strategy is key here—it encourages customers to consolidate their fragmented tools, which reduces complexity and costs while driving NGS ARR growth. In Q2 FY2026, NGS ARR rose 33% year-over-year to $6.3 billion.
TaskUs, Inc. (TASK) stands out as a leading provider of outsourced digital services and next-generation customer experience solutions. The company focuses on digital customer experience (Digital CX), trust and safety (monitoring user-generated content for compliance), and artificial intelligence (AI) services such as data labeling and annotation for machine learning models. From its headquarters in New Braunfels, Texas, TaskUs serves high-growth sectors like social media, e-commerce, gaming, streaming, food delivery, ride-sharing, technology, financial services, and healthcare.
WVE stock plunged approximately -52% over the past 30 days, driven primarily by disappointing high-dose data from the Phase 1 INLIGHT trial of obesity candidate WVE-007 on March 26, which erased prior gains from positive initial results. Over the past quarter, shares declined around -61%, reflecting high volatility in biotech sentiment amid clinical trial outcomes and broader sector pressures on clinical-stage firms
KOD stock surged +39% over the past 30 days, driven primarily by positive Phase 3 GLOW2 trial results for Zenkuda in diabetic retinopathy. Over the past quarter, shares gained +36%, reflecting anticipation of clinical catalysts and a successful $184 million capital raise.
Lam Research Corporation stands out as a leading supplier of semiconductor processing equipment essential for fabricating integrated circuits. The company designs, manufactures, markets, refurbishes, and services tools for deposition, etch, and clean processes, serving major chipmakers across the United States, China, Korea, Taiwan, Japan, and Europe. At its core, Lam's business revolves around innovative systems like ALTUS for film deposition and SABRE for electrochemical deposition, which are vital for advanced nodes in AI, memory, and logic chips.
Roblox Corporation (RBLX) runs a platform where millions of users create and dive into immersive 3D experiences. The business centers on a virtual economy: users buy Robux for in-game items, and creators cash out through the developer exchange (DevEx) program. In the online gaming space, Roblox stands out as a metaverse pioneer, going up against the likes of Epic Games' Fortnite and newer AI-driven platforms. The fundamentals reflect impressive user growth—daily active users (DAUs) reached 144 million in Q4 2025, a 69% jump year-over-year—but ongoing net losses underscore the heavy spending on infrastructure, AI, and safety. From what I see, this tension between growth and profitability has fueled much of the recent volatility in RBLX shares, as investors weigh strong engagement against shrinking margins.
Megan Holdings Limited (MGN) is a Malaysia-based company focused on the development, construction, maintenance, and upgrade of aquaculture and agriculture farms, along with related services. At its core, the business provides end-to-end solutions for shrimp farms, from design and building hatcheries to ongoing maintenance. It operates mainly in Sabah, Malaysia, across segments like aquaculture/agriculture, industrial solutions such as smart technologies, and investments in marketable securities.
Megan Holdings Limited (MGN), based in Kuala Lumpur and founded in 2020, focuses on developing, constructing, maintaining, and upgrading aquaculture and agriculture farms in Malaysia. The company operates in three segments—aquaculture and agriculture, industrial solutions like supplying smart technologies and machinery rentals, and investments in marketable securities—carving out a niche in engineering and construction within the Industrials sector. Its subsidiary status under Star Sprite Limited adds a layer of operational stability.
Pony AI Inc. (PONY) stands out as a leading player in autonomous mobility, dedicated to bringing self-driving technology to commercial use. Founded in 2016 and based in Guangzhou, China, the company operates across China, the U.S., and other international markets, offering robotaxi services, robotruck logistics, and licensing for intelligent driving solutions. Its business model leans heavily on asset-light partnerships with original equipment manufacturers (OEMs), transportation network companies (TNCs), and logistics platforms.
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney and metabolic diseases. In my view, the company's core strength lies in its proprietary Maze Compass platform, which uses human genetics and variant functionalization to identify and advance therapies targeting genetically defined patient populations.
In my view, JPM stands out as the largest U.S. bank by assets and market capitalization, commanding leading market shares across key segments. It holds approximately 11.1% of U.S. retail deposits, 23.6% of credit card sales volume, 8.4% of global investment banking fees, 11.8% of markets revenue, and 10% of treasury services revenue. This diversified "universal banking model" spans consumer and community banking, commercial and investment banking, and asset and wealth management, generating resilient revenue streams.
In recent sessions, WMT has held steady around $124, pulling back from February highs near $134. From what I see, this resilience stands out as the stock has outperformed broader indices year-to-date, thanks to its defensive role in groceries and essentials. Shoppers are leaning toward value options, and consistent volumes show ongoing institutional support. The premium valuation reflects confidence in Walmart's omnichannel progress and market share gains. Even with macro headwinds, I view WMT as a portfolio staple during uncertain times.
I've been following ANTX, a biopharmaceutical company based in Menlo Park, California, that develops novel small molecule therapeutics from its proprietary boron chemistry platform. The focus is on underserved areas like infectious diseases, with the lead candidate epetraborole advancing in Phase 3 trials for non-tuberculous mycobacterial (NTM) lung disease and acute melioidosis. The pipeline also includes AN2-502998 for chronic Chagas disease in preclinical stages, along with programs in oncology.
Tilly's, Inc. (TLYS) operates as a specialty retailer specializing in casual apparel, footwear, accessories, and hardgoods aimed at young men, women, boys, and girls. The company focuses on branded fashion inspired by action sports, surf, and skate culture, offering products like tops, bottoms, swimwear, backpacks, hats, and sunglasses from well-known brands such as Vans and Hurley. With approximately 223 stores in malls and lifestyle centers, complemented by e-commerce through www.tillys.com, Tilly's effectively combines physical and digital sales channels.
NKE shares are tumbling approximately 11% in premarket trading on April 1, 2026, sliding to near nine-year lows after the previous close of $52.82. The primary catalyst is Nike's weak Q4 fiscal 2026 guidance: management projected a 2%–4% revenue decline, sharply missing analyst expectations of approximately 1.9% growth.
CoreWeave (CRWV) Holds Steady on 2026 Revenue Targets in a Shifting AI Landscape